MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
InspireMD EBITDA 2011-2026 | NSPR
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA InspireMD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 211 M | 169 M | -14.6 M | -10.2 M | -9.66 M | -7.46 M | -8.05 M | -7.46 M | -13.3 M | -23.4 M | -14.9 M | -17.4 M | -13.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 211 M | -23.4 M | 18.5 M |
Quarterly EBITDA InspireMD
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -11.4 M | - | - | - | -7.34 M | - | - | - | -4.33 M | - | -4.48 M | -4.6 M | -4.44 M | - | -3.91 M | -3.36 M | -3.26 M | - | -2.07 M | -2.36 M | -1.97 M | - | -1.88 M | -2.11 M | -3.1 M | - | -1.86 M | -1.39 M | -1.91 M | - | -1.96 M | -2.21 M | -2.36 M | - | -1.62 M | -1.67 M | -1.98 M | - | -3.22 M | -3.44 M | -4.82 M | - | -6.3 M | -7.11 M | -5.48 M | - | -3.72 M | -4.1 M | -3.83 M | -4.37 M | -3.25 M | -7.55 M | -3.25 M | -8.24 M | -2.14 M | -2.17 M | -1.14 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.14 M | -11.4 M | -3.7 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aethlon Medical
AEMD
|
-9 M | $ 2.11 | 8.21 % | $ 3.29 M |  USA |
 |
AdaptHealth Corp.
AHCO
|
473 M | $ 10.42 | -1.65 % | $ 1.41 B | USA |
 |
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | USA |
 |
Alphatec Holdings
ATEC
|
-4.64 M | $ 12.6 | 2.61 % | $ 1.89 B | USA |
 |
Butterfly Network
BFLY
|
-65.5 M | $ 3.91 | 2.62 % | $ 828 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
8.53 M | $ 8.38 | -0.24 % | $ 602 M |  Israel |
 |
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | USA |
 |
Boston Scientific Corporation
BSX
|
4.98 B | $ 69.79 | 0.95 % | $ 103 B | USA |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-18 M | $ 3.96 | 1.02 % | $ 148 M |  France |
 |
CONMED Corporation
CNMD
|
120 M | $ 37.41 | 0.35 % | $ 1.16 B | USA |
 |
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-15.2 M | $ 0.65 | -8.13 % | $ 35.4 M | USA |
 |
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | USA |
 |
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | USA |
 |
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | USA |
 |
ClearPoint Neuro
CLPT
|
-18.8 M | $ 11.03 | 2.22 % | $ 298 M | USA |
 |
Establishment Labs Holdings
ESTA
|
-32.8 M | $ 63.48 | 0.21 % | $ 1.88 B |  Costa-rica |
 |
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | USA |
 |
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
FONAR Corporation
FONR
|
9.84 M | $ 18.42 | 0.22 % | $ 121 M | USA |
 |
InMode Ltd.
INMD
|
86.1 M | $ 13.43 | -0.81 % | $ 868 M | Israel |
 |
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | USA |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | USA |
 |
Abbott Laboratories
ABT
|
9.49 B | $ 109.95 | 1.8 % | $ 191 B | USA |
 |
Delcath Systems
DCTH
|
898 K | $ 9.81 | 3.81 % | $ 351 M | USA |
 |
Bio-Rad Laboratories
BIO
|
421 M | $ 261.24 | -0.59 % | $ 7.37 B | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.19 | 3.79 % | $ 1.33 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
70.8 M | $ 9.01 | -2.49 % | $ 694 M | USA |
 |
AxoGen
AXGN
|
-1.19 M | $ 32.84 | 1.55 % | $ 1.51 B | USA |
 |
Align Technology
ALGN
|
753 M | $ 169.45 | 3.18 % | $ 12.7 B | USA |
 |
Bruker Corporation
BRKR
|
437 M | $ 32.76 | -2.93 % | $ 4.88 K | USA |
 |
IRIDEX Corporation
IRIX
|
-8.91 M | $ 1.33 | 2.31 % | $ 21.5 M | USA |
 |
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
-5.79 M | $ 3.67 | 1.1 % | $ 151 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 17.11 | -1.16 % | $ 401 M | USA |
 |
Integer Holdings Corporation
ITGR
|
352 M | $ 84.12 | 1.34 % | $ 2.92 B | USA |
 |
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | USA |
 |
Second Sight Medical Products
EYES
|
-24.3 M | - | -0.97 % | $ 54.4 M | USA |